PRA's Central Review Services team, unique in the CRO industry, offers lupus-specific expertise in efficacy endpoint data correlation, standardized central medical review and grading, and investigator site training.
Explore related content and topics

Oral Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone
Hydrocodone bitartrate (HB) and acetaminophen (APAP) combination products are known to be abused via oral, intranasal, and intravenous…

Predicting Screen Failure Rates of Human Abuse Potential Studies
Human Abuse Potential (HAP) studies are required for New Drug Approvals of all drugs that have a potential psychoactive effect. The steps of…

Multi-stakeholder Collaboration Achieves Rapid Study Start-up for an Advanced Therapeutic
PRA worked with an emerging biotech firm to implement a first-in-human clinical trial using a live biotherapeutic product for a rare disease…